Cubist Pharmaceuticals said it is considering selling up to $100 million in common stock. In a regulatory filing, the Massachusetts firm, which produces treatments for skin infections, said it would use the money for general corporate purposes, including the commercialization of its products and debt repayment.

Full Story:

Related Summaries